. . . . . "Mitoxantrone" . . . "prostate cancer" . . . "ANLL" . "acute nonlymphocytic leukemia" . . . "pain" . . . "corticosteroids" . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . "2022-10-10T14:42:25.946268"^^ . . " Mitoxantrone in combination with corticosteroids is indicated as initial chemotherapy for the treatment of patients with pain related to advanced hormone-refractory prostate cancer. In combination with other approved drug(s) is indicated in the initial therapy of acute nonlymphocytic leukemia (ANLL) in adults. This category includes myelogenous, promyelocytic, erythroid acute leukemias." . "2.3.0" . "RSA" . "MIIBIjANBgkqhkiG9w0BAQEFAAOCAQ8AMIIBCgKCAQEApdULbl+/+pkVlq0fAzWmzfgIb+XMuQPKHMDVzUTWCZBjLfzORll42ptr52e4w7tTYkUKrBsQbx8lkjZWAlWiyh+xIK0oLFSdYRSt63kgiyRYBUOR+spcgmofb7f6JyftArPVTKhsWOMt/mcyNG9qc3lw8B/xuPmLteUWO33xWhfXQreTw1lsGUkZ1j4cB4X9HIuI20ktLYLCXaBauNHEJZ4qp6/Q2ATsJcw8tg7aRmFKXhrjM9maZ2+0cMg0Jpmn2UnDlPKXEA6Qq+qnvvQt8KFjIzP9FTMyvrWl8tTd0NCmS9VpooZJQ8We1lGMPXg5bMbe/bVkTf70fbFMf0RKrQIDAQAB" . "iOI43HixYHxKMCKE0/UndbE4LAuMqf/rPUoQv687lqG4jX/Jlq+J4IOnfzyY34f23kb321U2AO9apovSiXEM+9omcQi2lnulJqL4Jz78npCtVgswIrH/IDii3j4cAu5rxHMBx8wnBZ5fm1t9oGAJAtMfMq+N3WPE923qm7QG98LPoDFP+DKZQ8CvEeEYZLVuUuk6idnXtfSRh5n8fdFZ5GWrE2RfA0/Wr1yJP7Q0Wnge6sMTGwjUo3LRZAsTkyDUX5Alkl+M1WsWOd1UqPCmz/mN2fVJ0ZM3croxiVKoCmr6CEvh8F5iEX9ji1tuK0q1jrnqtbiuvy9jDSvBdwVPzw==" . . "2022-10-10T14:42:25.946268"^^ . .